Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: RE: email --

RE: email --

posted on Apr 24, 2006 07:30AM

I`m glad you put a fork in the ``recuring royalties vs. one time paymant`` debate.

IMO, it also shows the strength of TPL`s case when combined with two royalty payments by a penny stock -- and now a stock buy back plan. Without recurring revs, what do we think Pohl and the BOD believes the future holds for PTSC investors? IMO, a very strong statement.

These are not dumb guys, they want a very positive message to be sent through the ASM to stabilize the pps and to draw in investors.

Also, glad to see ANYTHING on ignite. My guess is the ASM will have a portion of the meeting dedicated to the potential this product provides PTSC and may be the focus of the after meeting demonstration. It would be interesting to know if there are any early adaptors on board with the ignite program -- not names, just the fact that the market has something coming utilizing PTSC`s newest toy.

John

Share
New Message
Please login to post a reply